Live

metabolic disorders

5 articles

Benzinga

Benzinga·Apr 22·Prnewswire

Viking Therapeutics to Report Q1 2026 Results; Obesity Drug VK2735 in Focus

Viking Therapeutics will report Q1 2026 earnings April 29 after market close, showcasing progress on obesity and metabolic disorder treatments.

VKTXfinancial resultsPhase 3 trials

Benzinga

Benzinga·Apr 10·Prnewswire

Viking Therapeutics Expands Investor Outreach With Spring Conference Circuit

Viking Therapeutics to present at two major biotech conferences in April 2026, conducting investor meetings in New York and Boston.

VKTXinvestor conferencesclinical trials

Benzinga

Benzinga·Mar 26·Prnewswire

Viking Therapeutics Completes Enrollment in Phase 3 VANQUISH-2 Obesity Trial

Viking Therapeutics finishes enrolling 1,000 patients in Phase 3 VANQUISH-2 trial of VK2735 for obesity treatment, with results expected in 2027.

VKTXPhase 3 clinical trialobesity treatment

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

The Motley Fool

The Motley Fool·Mar 16·Jonathan Ponciano

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.

CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GlobeNewswire Inc.

GlobeNewswire Inc.·Mar 4·Researchandmarkets.Com

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.

AMGNPFELLYNVORHHBY+1weight lossdiabetes treatment